Revenue from AbbVie's inflammation treatment Humira will crash to $3 billion annually by 2025, an analyst said Thursday — but he upgraded AbbVie stock ahead of its Allergan buyout.

source https://finance.yahoo.com/m/2fca5977-51a6-351d-8bac-c491bde49558/humira-sales-will-crash-to-%243.html?.tsrc=rss